228 related articles for article (PubMed ID: 26566105)
41. Vorapaxar in the treatment of cardiovascular diseases.
Tantry US; Bliden KP; Chaudhary R; Novakovic M; Rout A; Gurbel PA
Future Cardiol; 2020 Sep; 16(5):373-384. PubMed ID: 32308016
[TBL] [Abstract][Full Text] [Related]
42. Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial).
Cornel JH; Tricoci P; Lokhnygina Y; Moliterno DJ; Wallentin L; Armstrong PW; Aylward PE; Clare RM; Chen E; Leonardi S; Van de Werf F; White HD; Held C; Strony J; Mahaffey KW; Harrington RA
Am J Cardiol; 2015 May; 115(10):1325-32. PubMed ID: 25776457
[TBL] [Abstract][Full Text] [Related]
43. Peripheral Revascularization in Patients With Peripheral Artery Disease With Vorapaxar: Insights From the TRA 2°P-TIMI 50 Trial.
Bonaca MP; Creager MA; Olin J; Scirica BM; Gilchrist IC; Murphy SA; Goodrich EL; Braunwald E; Morrow DA
JACC Cardiovasc Interv; 2016 Oct; 9(20):2157-2164. PubMed ID: 27765312
[TBL] [Abstract][Full Text] [Related]
44. Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar.
Cho JR; Rollini F; Franchi F; Ferrante E; Angiolillo DJ
Vasc Health Risk Manag; 2014; 10():177-88. PubMed ID: 24729713
[TBL] [Abstract][Full Text] [Related]
45. Vorapaxar and Amyotrophic Lateral Sclerosis: Coincidence or Adverse Association?
Serebruany VL; Fortmann SD; Hanley DF; Kim MH
Am J Ther; 2017; 24(2):e139-e143. PubMed ID: 28267691
[TBL] [Abstract][Full Text] [Related]
46. Coronary stent thrombosis with vorapaxar versus placebo: results from the TRA 2° P-TIMI 50 trial.
Bonaca MP; Scirica BM; Braunwald E; Wiviott SD; O'Donoghue ML; Murphy SA; Morrow DA
J Am Coll Cardiol; 2014 Dec; 64(22):2309-17. PubMed ID: 25465416
[TBL] [Abstract][Full Text] [Related]
47. Platelet transfusion reverses bleeding evoked by triple anti-platelet therapy including vorapaxar, a novel platelet thrombin receptor antagonist.
Cai TQ; Wickham LA; Sitko G; Michener MS; Raubertas R; Handt L; Chintala M; Seiffert D; Forrest M
Eur J Pharmacol; 2015 Jul; 758():107-14. PubMed ID: 25857224
[TBL] [Abstract][Full Text] [Related]
48. Role for Thrombin Receptor Antagonism With Vorapaxar in Secondary Prevention of Atherothrombotic Events: From Bench to Bedside.
Moon JY; Franchi F; Rollini F; Angiolillo DJ
J Cardiovasc Pharmacol Ther; 2018 Jan; 23(1):23-37. PubMed ID: 28565918
[TBL] [Abstract][Full Text] [Related]
49. Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial.
Ungar L; Clare RM; Rodriguez F; Kolls BJ; Armstrong PW; Aylward P; Held C; Moliterno DJ; Strony J; Van de Werf F; Wallentin L; White HD; Tricoci P; Harrington RA; Mahaffey KW; Melloni C
J Am Heart Assoc; 2018 Dec; 7(24):e009609. PubMed ID: 30526198
[TBL] [Abstract][Full Text] [Related]
50. Vorapaxar and optimal aspirin dose: The FDA outlook.
Serebruany VL; Fortmann SD; Kim MH
Int J Cardiol; 2016 Jan; 203():903-5. PubMed ID: 26609688
[TBL] [Abstract][Full Text] [Related]
51. Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trial.
Harskamp RE; Clare RM; Ambrosio G; Held C; Lokhnygina Y; Moliterno DJ; White HD; Aylward PE; Armstrong PW; Mahaffey KW; Harrington RA; Van de Werf F; Wallentin L; Strony J; Tricoci P
Eur Heart J Acute Cardiovasc Care; 2017 Mar; 6(2):155-163. PubMed ID: 26895973
[TBL] [Abstract][Full Text] [Related]
52. Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions.
White HD
Am Heart J; 2011 Mar; 161(3):450-61. PubMed ID: 21392598
[TBL] [Abstract][Full Text] [Related]
53. State transition model: vorapaxar added to standard antiplatelet therapy to prevent thrombosis post myocardial infarction or peripheral artery disease.
Du M; Chase M; Oguz M; Davies G
Curr Med Res Opin; 2017 Sep; 33(9):1535-1543. PubMed ID: 28277861
[TBL] [Abstract][Full Text] [Related]
54. Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50.
Bonaca MP; Scirica BM; Creager MA; Olin J; Bounameaux H; Dellborg M; Lamp JM; Murphy SA; Braunwald E; Morrow DA
Circulation; 2013 Apr; 127(14):1522-9, 1529e1-6. PubMed ID: 23501976
[TBL] [Abstract][Full Text] [Related]
55. Adjunctive therapies to reduce thrombotic events in patients with a history of myocardial infarction: role of vorapaxar.
Farag M; Patel H; Gorog DA
Drug Des Devel Ther; 2015; 9():3801-9. PubMed ID: 26229441
[TBL] [Abstract][Full Text] [Related]
56. Vorapaxar: a novel protease-activated receptor-1 inhibitor.
Gurbel PA; Jeong YH; Tantry US
Expert Opin Investig Drugs; 2011 Oct; 20(10):1445-53. PubMed ID: 21819272
[TBL] [Abstract][Full Text] [Related]
57. Universal Classification System Type of Incident Myocardial Infarction in Patients With Stable Atherosclerosis: Observations From Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-TIMI 50.
Kidd SK; Bonaca MP; Braunwald E; De Ferrari GM; Lewis BS; Merlini PA; Murphy SA; Scirica BM; White HD; Morrow DA
J Am Heart Assoc; 2016 Jul; 5(7):. PubMed ID: 27431644
[TBL] [Abstract][Full Text] [Related]
58. Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial.
Leonardi S; Tricoci P; White HD; Armstrong PW; Huang Z; Wallentin L; Aylward PE; Moliterno DJ; Van de Werf F; Chen E; Providencia L; Nordrehaug JE; Held C; Strony J; Rorick TL; Harrington RA; Mahaffey KW
Eur Heart J; 2013 Jun; 34(23):1723-31. PubMed ID: 23530022
[TBL] [Abstract][Full Text] [Related]
59. Approval of the first protease-activated receptor antagonist: Rationale, development, significance, and considerations of a novel anti-platelet agent.
French SL; Arthur JF; Tran HA; Hamilton JR
Blood Rev; 2015 May; 29(3):179-89. PubMed ID: 25467961
[TBL] [Abstract][Full Text] [Related]
60. Efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function.
Correa S; Bonaca MP; Scirica BM; Murphy SA; Goodrich EL; Morrow DA; O'Donoghue ML
J Thromb Thrombolysis; 2019 Apr; 47(3):353-360. PubMed ID: 30511258
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
